Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

GlobeNewswire January 9, 2024

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS(TM) (Anthrax Vaccine Adsorbed, Adjuvanted)

GlobeNewswire November 28, 2023

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

GlobeNewswire November 24, 2023

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

GlobeNewswire November 8, 2023

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

GlobeNewswire October 30, 2023

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

GlobeNewswire October 19, 2023

Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic

PR Newswire October 16, 2023

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

GlobeNewswire October 2, 2023

Emergent BioSolutions' NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

GlobeNewswire August 30, 2023

Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600

PR Newswire August 21, 2023

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

GlobeNewswire August 8, 2023

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire August 8, 2023

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

GlobeNewswire August 8, 2023

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga(TM) Treatment for Ebola

GlobeNewswire July 31, 2023

Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023

GlobeNewswire July 25, 2023

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS(TM) (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

GlobeNewswire July 20, 2023

Emergent BioSolutions Announces CEO Transition

GlobeNewswire June 27, 2023

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

GlobeNewswire May 15, 2023

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

GlobeNewswire May 11, 2023

Emergent BioSolutions Reports Financial Results For First Quarter 2023

GlobeNewswire May 9, 2023